INDIANAPOLIS , March 24, 2020 /PRNewswire/ -- To keep the diabetes community informed about important developments from the COVID-19 crisis, Eli Lilly and Company (NYSE: LLY) today is providing updates related to insulin supply and affordability: As we announced on March 3 , Lilly does not

INDIANAPOLIS , March 23, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today provided an update on the company's clinical trial activities in light of the COVID-19 pandemic. The company will delay most new study starts and pause enrollment in most ongoing studies.

INDIANAPOLIS , March 22, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will offer drive-through testing for SARS-CoV-2, the virus that causes COVID-19, to Indianapolis area health care workers beginning Monday, March 23 , as a service to the community and in an effort to protect health care

RIDGEFIELD, Conn. and INDIANAPOLIS, March 20, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has issued a complete response letter for the supplemental New Drug Application (sNDA) of the investigational medicine empagliflozin 2.5 mg as an adjunct to insulin for adults with type 1

INDIANAPOLIS , March 20, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) announced today that Kathryn Beiser will join the company on April 6, 2020 as vice president, global communications. In this role, Beiser will oversee all aspects of the company's corporate communications strategy,

INDIANAPOLIS , March 18, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE:LLY) announced today its scientists are partnering with the Indiana State Department of Health (ISDH), with support from the Food and Drug Administration (FDA), to accelerate testing in Indiana for SARS-CoV-2, the virus that

Recognition reinforces baricitinib's potential to be the first FDA-approved medicine for individuals living with alopecia areata INDIANAPOLIS , March 16, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S.

AbCellera and Lilly will select from 500+ unique antibodies isolated from one of the first U.S. patients who recovered from COVID-19 to create antibody therapeutics for treatment and prevention of COVID-19 VANCOUVER, British Columbia and INDIANAPOLIS , March 12, 2020 /PRNewswire/ -- AbCellera and

-- FDA Fast Track designation is for the investigation of potential new therapies that treat serious conditions and fulfill an unmet medical need RIDGEFIELD, Conn. and INDIANAPOLIS, March 12, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the

Participation Adds to Lilly's Suite of Affordability Solutions INDIANAPOLIS , March 11, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) is proud to announce its planned participation in the new Part D Senior Savings Model, announced today by the Centers for Medicare & Medicaid Services